NASDAQ · Biotechnology

Celyad Oncology S.A. (CYAD) Stock

$0.47 -12.96% NASDAQ: CYAD Healthcare

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers.

Valuation

MetricValue
Price$0.47
Market Cap$14.24M
P/E Ratio-2.95
P/B Ratio2.71
P/S Ratio67.18
EPS (TTM)$-0.14
52-Week High$3.07
52-Week Low$0.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-109.67%
ROA-35.77%
ROCE-43.88%
Gross Margin93.55%
Operating Margin—
Net Margin—
Debt/Equity0.17
Current Ratio3.79

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-17.0M$-26.0M$-41.0M$-8.0M$-6.0M
Net Profit$-18.0M$-27.0M$-41.0M$-8.0M$-6.0M
EPS$-1.26$-1.70$-1.81$-0.33$-0.14
Op Margin-339740.0%——-8291.2%-3149.5%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$66.0M$80.0M$20.0M$16.0M—
Total Liabilities$35.0M$36.0M$15.0M$10.0M—
Cash$17.0M$30.0M$12.0M$7.0M—
Borrowings$4.0M$3.0M$0$1.0M$0

Latest News

Gold prices today, Thursday, July 30, 2026: Gold prices crest $4,100 after Fed holds rates steady Yahoo Personal Finance · Jul 30, 2026 Huge News For SpaceX Stock Fans GuruFocus.com · Jul 30, 2026 George and Amal Clooney flee French home due to wildfire AFP · Jul 30, 2026 20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour GlobeNewswire · Jul 30, 2026 Microsoft Stock Jumps as Azure Passes $100 Billion in Revenue GuruFocus.com · Jul 30, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-28.0M$-27.0M$-28.0M$-15.0M—
Investing Cash Flow$0$-1.0M$7.0M$0—
Financing Cash Flow$7.0M$41.0M$4.0M$10.0M—
Net Cash Flow$-22.0M$13.0M$-18.0M$-5.0M—
Free Cash Flow$-28.0M$-27.0M$-28.0M$-16.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-1.15
FCF Yield-128.85%
Quick Ratio3.79
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Celyad Oncology S.A.

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phase 1b trials for patients with metastatic colorectal cancer. Another allogeneic, shRNA-based CAR-T candidate, CYAD-211, is in Phase 1 for individuals suffering from relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T therapy, is being evaluated in Phase 1 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, Celyad is developing CYAD-203. This is a non-gene edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 (IL-18) alongside natural killer group 2D ligands (NKG2D), targeting solid tumors. Celyad has also forged strategic alliances. It holds a licensing agreement with Novartis International AG concerning US patents for allogeneic CAR-T cell technology. Furthermore, the company has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to establish a second non-gene-edited allogeneic platform. Founded in 2004, the company was initially named Celyad SA, but rebranded to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.

Celyad Oncology S.A. is headquartered in BE.

Celyad Oncology S.A. (CYAD) stock trades at $0.47 with a market capitalization of $14.24M. The stock is valued at a price-to-earnings (P/E) ratio of -2.95, price-to-book of 2.71, price-to-sales of 67.18. Over the past 52 weeks the stock has ranged between $0.15 and $3.07, and currently trades 84.7% below its 52-week high.

On profitability, Celyad Oncology S.A. generates a return on equity (ROE) of -109.67%, return on capital employed of -43.88%.

Official website: www.celyad.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides